NZ502830A - Flat systems for cutaneous and percutaneous administration involving a sticking-plaster as an information carrier relating to therapy, and method for producing such a plaster - Google Patents
Flat systems for cutaneous and percutaneous administration involving a sticking-plaster as an information carrier relating to therapy, and method for producing such a plasterInfo
- Publication number
- NZ502830A NZ502830A NZ502830A NZ50283098A NZ502830A NZ 502830 A NZ502830 A NZ 502830A NZ 502830 A NZ502830 A NZ 502830A NZ 50283098 A NZ50283098 A NZ 50283098A NZ 502830 A NZ502830 A NZ 502830A
- Authority
- NZ
- New Zealand
- Prior art keywords
- coding
- plaster
- coding system
- information
- active ingredient
- Prior art date
Links
- 239000011505 plaster Substances 0.000 title claims abstract description 29
- 238000002560 therapeutic procedure Methods 0.000 title claims abstract description 4
- 238000004519 manufacturing process Methods 0.000 title claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 34
- 239000000853 adhesive Substances 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 11
- 230000001225 therapeutic effect Effects 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 9
- 230000000694 effects Effects 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 8
- 230000001070 adhesive effect Effects 0.000 claims description 7
- 229940079593 drug Drugs 0.000 claims description 7
- 239000000729 antidote Substances 0.000 claims description 4
- 239000011159 matrix material Substances 0.000 claims description 4
- 206010020751 Hypersensitivity Diseases 0.000 claims description 3
- 239000002313 adhesive film Substances 0.000 claims description 3
- 230000007815 allergy Effects 0.000 claims description 2
- 229940075522 antidotes Drugs 0.000 claims description 2
- 231100001261 hazardous Toxicity 0.000 claims description 2
- 239000004615 ingredient Substances 0.000 claims description 2
- 208000024891 symptom Diseases 0.000 claims description 2
- 239000013543 active substance Substances 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 239000010410 layer Substances 0.000 description 29
- 230000009471 action Effects 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 239000012790 adhesive layer Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 229920001169 thermoplastic Polymers 0.000 description 3
- 239000004416 thermosoftening plastic Substances 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 230000003356 anti-rheumatic effect Effects 0.000 description 2
- 239000003435 antirheumatic agent Substances 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 238000007639 printing Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 229940100640 transdermal system Drugs 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000006994 Precancerous Conditions Diseases 0.000 description 1
- 239000004820 Pressure-sensitive adhesive Substances 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 238000004159 blood analysis Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010169 landfilling Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000012907 medicinal substance Substances 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000011241 protective layer Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000246 remedial effect Effects 0.000 description 1
- 238000007650 screen-printing Methods 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000003746 surface roughness Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940126703 systemic medication Drugs 0.000 description 1
- 238000007669 thermal treatment Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- G—PHYSICS
- G09—EDUCATION; CRYPTOGRAPHY; DISPLAY; ADVERTISING; SEALS
- G09F—DISPLAYING; ADVERTISING; SIGNS; LABELS OR NAME-PLATES; SEALS
- G09F3/00—Labels, tag tickets, or similar identification or indication means; Seals; Postage or like stamps
- G09F3/08—Fastening or securing by means not forming part of the material of the label itself
- G09F3/10—Fastening or securing by means not forming part of the material of the label itself by an adhesive layer
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Theoretical Computer Science (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Disclosed are flat sticking systems - cutaneous and transcutaneous administration - involving a sticking-plaster as an information carrier, characterized in that said plaster is provided with an electronically recognizable coding for information relative to the therapy.
Description
I Identification for adhesive sheet-like dermal and transdermal therapeutic administration forms using an adhesive plaster as information carrier, and process for its production.
Adhesive sheet-like systems are known for the therapy of a large number of disorders and have been outstandingly successful in many therapeutic application 10 areas.
Systems of this type have long been known as superficially acting systems for application to the skin with a surface (topical) action as antirheumatic plasters 15 or as plasters for treating precancerous states with the active ingredient 5-fluorouracil. Transdermal therapeutic systems (TTS) with a systemic action are also achieving increasing importance. Their advantage comprises, for example, controlled, relatively long-term delivery of 2 0 active ingredients through the skin. A transdermal system of this type has an impermeable and nonadhesive backing layer to prevent unwanted emergence of active ingredients to the outside, and a pressure-sensitive adhesive layer, for the required adhesion to the skin, which may simul-25 taneously contain active ingredient, and a detachable protective layer, which normally has an adhesive finish, to prevent loss of active ingredient during storage of a TTS.
As the result of medical and pharmacological 3 0 research and, in particular, to improve the possibilities of medicinal treatment of patients, novel active ingredient combinations and administration forms are continually being developed and proposed for medical application. According to a study at the University of Ottawa and, in 35 particular, the Heart Institute there, documented in Mussivand et al., ASAIO Journal 1995; 41: M253-M258, it is reported that 25,000 novel medical articles are launched on the market each year.
Hence modern medicine confronts both the physician and the patients with an immense number of medicines, of which it is still possible to acquire without prescription a comparatively large proportion (for example antirheumatic plasters, nicotine plasters for stopping smoking 10 etc.). Many patients are dependent on long-term medication, for example for lowering high blood pressure etc. They are thus often exposed to the reaction of one or more medicinal substances. One disadvantage of the use and of the often inadvertent misuse of numerous medicines con-15 sists of the possible interactions with other medicinal substances or particular consumables (for example alcohol) and an increase in side effects with the risk of harmful levels of active ingredient in a patient's body. In some cases, a critical problem may arise from this if a patient 2 0 declines into a helpless, for example comatose unconscious state, for example because of excessive alcohol consumption, drug use or such an acute interaction, and there is no information available to the attending emergency physician about all the medicinal substances or active ingredi-25 ents taken by the patient. Such information about the nature of the harmful pharmaceuticals acting inside the patient can in such a case be obtained only by blood analysis, which is time-consuming and requires elaborate apparatus, which would in an acute case be available much 3 0 too late, if at all. As a consequence, in such a case, the physician has no possibility of correctly assessing, and for example determining with antidotes, the effect of a harmful active ingredient, or supplementing the intake of a medicinal substance which is vital for the patient in a 35 controlled manner. The physician is equally unable to decide in such cases whether the maintenance and possible renewal of the medication is also indicated in such cases. It is obvious to expect there to be a need for precise identification of active ingredient plasters in respect of 5 constitution and ingredients so that, for the purposes of disposal, they can be graded into pure grades, disposed of correspondingly appropriately or passed on for recovery of active ingredients.
In view of the increasingly large number of dif ferent systems already on the market now - there are more than 40 different basic types of active ingredient patterns - it is a particularly important necessity to be able to identify comprehensively each one, especially when 15 the information from pack insert and other accompanying information is unavailable.
DE 195 19 593 CI discloses a transdermal therapeutic system with a backing layer of thermoplastic 20 material consisting of a laminate of a low-melting thermoplastic located on the outside and of a higher-melting thermoplastic facing the skin, of a permanent identifying coding applied to this backing layer and consisting of locally varying surface characteristics, surface thickness 25 or surface roughness of this backing layer, and of an active part containing the active ingredient. In this case, the invention consists of producing this coding of the backing layer by the action of pressure, heat, ultrasound or abrasion.
Limits of utilizability of the application of the known identifying coding emerge from the fact that the action of pressure or heat may be harmful for many active ingredient-containing plasters. In addition, there are 3 5 comparatively narrow limits on the capacity of a coding which can be produced by varying the surface characteristics of the backing layer of a plaster. In addition, production thereof requires an additional concluding operation, for example on the fabricating system.
The abovementioned article from the University of Ottawa Heart Institute discloses a transcutaneous energy aTir? information system with which implants, defibrillators, circulatory stabilisers, biosensors etc. can be 10 supplied with energy using a remote-controlled connection system a-nn can be monitored with respect to the information generated by these implants. The range of applications of such devices and methods is, however, restricted to stationary facilities and is unsuitable, because of the 15 great complexity both of the apparatus and of the overall technique, for identifying transdermal therapeutic systems .
The invention is based on the object, starting 2 0 from the abovementioned state of the art, of indicating an identification for both transdermal therapeutic ana non-transaermal administration forms using a plaster as information carrier, and processes for producing it, which provides information about properties, amount, risks and/or 25 side effects without difficulty and with a comparatively large range of information, or to at least provide a useful alternative.
The object is achieved by an identification in which the plaster is provided with an electronically 3 0 identifiable coding.
Such a coding has the advantage that it can be performed or applied by known means and it has a comparatively large storage capacity for information and can be 3 5 decoded with available electronic readers which are pos- INTELLECTUAL PROPERTY OFFICE OF N.Z. 1 9 JUN 2001 RECEIVED sessed by or can be carried by every physician, every pharmacy, every ambulance or every hospital ward.
One embodiment provides for the coding being de-5 signed in the form of electronically readable numbers or letters or in the form of a barcode on the side of the plaster facing away from the skin. It is possible to store comparatively-extensive information texts on a coding field which is, for example, of the size of a normal 10 postage stamp. The coding is decoded without difficulty using an optical IR reading device.
It is, however, also possible advantageously to make sure that the coding on the side of the plaster 15 facing away from the skin is designed in the form of a microchip like one applied, for example, to cards given to those insured by health insurance offices. The latter have, for example, dimensions corresponding to about half the area of a postage stamp, can be produced at low cost 2 0 and can be applied to a plaster.
However, the coding can also be designed on the side of the plaster facing away from the skin in the form of a magnetic strip, similar to the magnetic strip pro-25 vided on a bank card. Finally, the coding may be present on the adhesive-free side of an adhesive film which can be stuck onto the plaster before or after its application to a patient's skin. 3 0 The identification according to the invention pro vides for the coding to comprise information about the nature and amount of the active ingredient present in the plaster and, appropriately, all the other materials. The coding provided for identifying the administration forms 35 can, however, also advantageously contain further informa tion about, for example, side effects of the therapeutic active ingredient, incompatibilities with other active ingredients and other noteworthy peculiarities. Finally, it is also possible to apply information required for dis-5 posal - grading, processing, landfilling or thermal treatment. The identification can very advantageously be supplemented, for example, by the coding containing instzructions for administration of antidote in the case of evident occurrence of hazardous symptoms, such as 10 overdosage of the active ingredient or acute side effects. A particular advantage of the identification is that personal data about the wearer of the dermal or transdermal system can be stored in coded form. It is possible specifically for patients at risk with an extensive med-15 ical history to include data about existing allergies, intolerance of medicines, etc. as patient-specific information content in the coding.
The general structure of basic TTS types is de-2 0 scribed, for example, by Y.W. Chien, "Developmental Concepts and Practice in Transdermal Therapeutic Systems" in Transdermal Controlled Systemic Medications, ed. by Y.W. Chien, Marcel Dekker, New York (1987), p. 25-81. The coding can be present in an active ingredient-containing 2 5 or active ingredient-free layer of the TTS.
A preferred embodiment contains the coding in a separate layer located on the backing layer of a TTS consisting of backing layer and active ingredient-containing 3 0 self-adhesive matrix layer.
Another preferred embodiment contains the coding in the backing layer of a TTS consisting of backing layer and active ingredient-containing self-adhesive matrix 3 5 layer.
Another preferred embodiment contains the coding in a separate layer which is located between the backing layer and the active ingredient-containing self-adhesive 5 matrix layer of a TTS.
Another preferred embodiment contains the coding in a separate layer located on the backing layer of a TTS consisting of backing layer, active ingredient-containing reservoir, membrane controlling the rate of release of the active ingredient, and a self-adhesive layer.
Another preferred embodiment contains the coding in the backing layer of a TTS consisting of backing layer, active ingredient-containing reservoir, membrane controlling the rate of release of the active ingredient, and a self-adhesive layer.
Another preferred embodiment contains the coding 2 0 in a separate layer located underneath the backing layer of a TTS consisting of backing layer, active ingredient-containing reservoir, membrane controlling the rate of release of the active ingredient and a self-adhesive layer.
A process for producing an identification of the generic type according to the precharacterizing clause of Claim 1 is characterized in that the coding is incorporated into or applied to the plaster during preparation 3 0 thereof. It is possible and advantageous to apply the coding to the plaster, for example, in a printing process such as screen printing or tampon printing or the like. The coding can also be applied to the plaster using a self-adhesive carrier provided with the coding.
Finally, an advantageous process for producing an identification of the plaster provides for storing the coding in a separate layer of a multilayer plaster or in the active ingredient-containing layer or in the outer 5 covering layer.
The identification for both transdermal therapeutic and non-transdermal administration forms using a plaster as information carrier eliminates in a very advan-10 tageous manner risk factors which are not always recognizable sufficiently rapidly, for example from active ingredient combinations which react together to give harmful side effects, or associated with a first-pass effect as a consequence of a damaged TTS or an overdosage, fur-15 thermore from allergic reactions or the consequences of the use of an active ingredient after its expiry date. The identification according to the invention makes it possible in such cases for the physician to remedy serious complications with specific remedial procedures, espe-2 0 cially in cases of life-threatening conditions.
To this extent the invention achieves the object stated at the outset in an optimal manner.
Claims (17)
1. Electronically readable coding system for information relevant to therapy, having a layer-like information carrier which can be separately fixed as an adhesive film or is part of a plaster on the side of the plaster facing away from the skin, said coding encompassing at least one information about the nature and amount of active substance(s), side effects, incompatibilities, possible antidotes and patient-specific specialities.
2. Coding system according to claim 1, wherein the coding is provided on or in the backing layer, or between the backing layer and the matrix of a transdermal therapeutic system.
3. Coding system according to claim 1, wherein the coding is designed in the form of a barcode on the side of the plaster facing away from the skin.
4. Coding system according to claim 1, wherein the coding is designed in the form of a microchip on the side of the plaster facing away from the skin.
5. Coding system according to claim 1, wherein the coding is designed in the form of a magnetic strip on the side of the plaster facing away from the skin.
6. Coding system according to claim 1, wherein the coding is present on the adhesive-free side of an adhesive film which can be stuck onto the plaster before or after its application to a patient's skin.
7. Coding system according to one or more of claims 1-5, wherein the coding contains information about the nature and amount of the active ingredient present in the plaster. INTELLECTUAL PROPERTY OFFICE OF N.Z. 1 9 JUN 2001 RECEIVED - 10 - 502830
8. Coding system according to one or more of claims 1-6, wherein the coding contains further information about, for example, side effects of the transdermal active ingredient, incompatibilities with other active ingredients and other noteworthy peculiarities.
9. Coding system according to one or more of claims 1-7, wherein the coding contains instructions for administration of antidote in the case of evident occurrence of hazardous symptoms.
10. Coding system according to one or more of claims 1-5, wherein the coding contains information about the justifiability of maintaining the administration.
11. Coding system according to one or more of claims 1-5, wherein the coding contains information about the constitution and composition in connection with disposal, especially data for grading, for recovering ingredients and for final destruction.
12. Coding system according to one or more of claims 1-5, wherein the coding contains information with patient-specific data.
13. Coding system according to claim 12, wherein the patient-specific data is about existing allergies and/or intolerance of medicines.
14. Process for the production of an identification for sheet-like adhesive systems, wherein the coding is applied to the plaster using a self adhesive carrier provided with the coding.
15. Process for the production of an identification for sheet-like adhesive systems, wherein the coding is introduced into a separate layer of a multilayer plaster or into the active ingredient-containing layer or into the outer covering layer. INTELLECTUAL PROPERTY OFFICE OF N.Z. 1 9 JUN 2001 RECEIVED 11
16. Electronically readable coding system according to any one of claims 1 to 13, substantially as herein described.
17. Process according to claim 14 or claim 15, substantially as herein described. END OF CLAIMS INTELLECTUAL PROPERTY OFFICE OF N.Z. 1 9 JUN 2001 RECEIVED END
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19736520A DE19736520A1 (en) | 1997-08-22 | 1997-08-22 | New adhesive plaster containing electronic information |
| PCT/EP1998/004846 WO1999009960A1 (en) | 1997-08-22 | 1998-08-04 | Flat systems for cutaneous and percutaneous administration involving a sticking-plaster as an information carrier, and method for producing such a plaster |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ502830A true NZ502830A (en) | 2001-08-31 |
Family
ID=7839806
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ502830A NZ502830A (en) | 1997-08-22 | 1998-08-04 | Flat systems for cutaneous and percutaneous administration involving a sticking-plaster as an information carrier relating to therapy, and method for producing such a plaster |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP1007016A1 (en) |
| JP (1) | JP2001513547A (en) |
| KR (1) | KR20010023176A (en) |
| AU (1) | AU737379B2 (en) |
| CA (1) | CA2299715A1 (en) |
| DE (1) | DE19736520A1 (en) |
| HU (1) | HUP0004184A3 (en) |
| ID (1) | ID24885A (en) |
| IL (1) | IL134386A0 (en) |
| NO (1) | NO20000814L (en) |
| NZ (1) | NZ502830A (en) |
| PL (1) | PL338736A1 (en) |
| SK (1) | SK2322000A3 (en) |
| TR (1) | TR200000408T2 (en) |
| WO (1) | WO1999009960A1 (en) |
| ZA (1) | ZA987580B (en) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10141836A1 (en) * | 2001-08-27 | 2003-03-27 | Hartmann Paul Ag | Medical kit for use in the supply of probe or catheter exit sites |
| AU5104399A (en) | 1998-07-20 | 2000-02-07 | William Neil Jones | A method of individually tracking and identifying a drug delivery device |
| DE19950295A1 (en) * | 1999-10-19 | 2001-04-26 | Beiersdorf Ag | Foil-based dressing material with imprint |
| GB9928511D0 (en) * | 1999-12-03 | 2000-02-02 | Secr Defence Brit | Orally administrable pharmaceutical product and method of fabrication therefor |
| US6808522B2 (en) | 1999-12-10 | 2004-10-26 | Massachusetts Institute Of Technology | Microchip devices for delivery of molecules and methods of fabrication thereof |
| EP1688132A3 (en) * | 1999-12-10 | 2009-10-07 | Massachussetts Institute of Technology | Microchip devices for delivery of molecules and methods of fabrication thereof |
| CA2399842C (en) | 2000-03-02 | 2006-11-14 | Microchips, Inc. | Microfabricated devices for the storage and selective exposure of chemicals and devices |
| DE10015930A1 (en) * | 2000-03-30 | 2001-10-18 | Dieter Hafner | Carrier for chemical, pharmaceutical or cosmetic substances is provided with at least one section with encoded information which is readable by a code reading device |
| AU2001265128A1 (en) | 2000-05-30 | 2001-12-11 | Massachusetts Institute Of Technology | Methods and devices for sealing microchip reservoir devices |
| DE102006011340A1 (en) * | 2006-03-09 | 2007-09-20 | Grünenthal GmbH | Active substance-containing patches with improved handling |
| DE102016105889A1 (en) * | 2016-03-31 | 2017-10-05 | Amw Gmbh | Transdermal application system with information layer |
| WO2019005852A1 (en) * | 2017-06-27 | 2019-01-03 | Lts Lohmann Therapy Systems, Corp. | Self-reminding patch |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4460368A (en) * | 1981-10-29 | 1984-07-17 | Almedco, Inc. | Trans-dermal medication system |
| ES2019275B3 (en) * | 1985-10-09 | 1991-06-16 | Desitin Arzneimittel Gmbh | METHOD FOR THE PRODUCTION OF A METHOD OF ADMINISTRATION AND DOSAGE FOR REACTIVE DRUGS OR OTHER ACTIVE PRINCIPLES. |
| DE3630603A1 (en) * | 1986-09-09 | 1988-03-10 | Desitin Arzneimittel Gmbh | PHARMACEUTICAL AND DOSAGE FORM FOR MEDICINAL ACTIVE SUBSTANCES, REAGENTS OR THE LIKE, AND METHOD FOR THE PRODUCTION THEREOF |
| DE4223004A1 (en) * | 1992-07-13 | 1994-01-20 | Liedtke Pharmed Gmbh | Single-dose semi-solid topical dosage form for transdermal therapy |
| DE9409784U1 (en) * | 1994-06-10 | 1994-08-11 | Effner Biomet Gmbh, 12247 Berlin | Device for the transdermal application of active substances |
| JPH08712A (en) * | 1994-06-27 | 1996-01-09 | Olympus Optical Co Ltd | Medicament with two dimensional data code |
| DE19519593C1 (en) * | 1995-05-29 | 1996-08-29 | Horstmann Michael | Transdermal therapeutic system with thermoplastic back layer |
| DE19524083C2 (en) * | 1995-07-01 | 2000-07-06 | Lohmann Therapie Syst Lts | Process for the disposal of transdermal application hazardous waste |
| US5700998A (en) * | 1995-10-31 | 1997-12-23 | Palti; Yoram | Drug coding and delivery system |
| DE19708674C2 (en) * | 1996-03-25 | 2002-02-07 | Lohmann Therapie Syst Lts | Transdermal therapeutic system with a drug-containing film layer and a soluble release layer, and a method for its preparation |
| US5797898A (en) * | 1996-07-02 | 1998-08-25 | Massachusetts Institute Of Technology | Microchip drug delivery devices |
-
1997
- 1997-08-22 DE DE19736520A patent/DE19736520A1/en not_active Withdrawn
-
1998
- 1998-08-04 NZ NZ502830A patent/NZ502830A/en unknown
- 1998-08-04 EP EP98946274A patent/EP1007016A1/en not_active Withdrawn
- 1998-08-04 HU HU0004184A patent/HUP0004184A3/en unknown
- 1998-08-04 KR KR1020007001802A patent/KR20010023176A/en not_active Withdrawn
- 1998-08-04 TR TR2000/00408T patent/TR200000408T2/en unknown
- 1998-08-04 AU AU93387/98A patent/AU737379B2/en not_active Ceased
- 1998-08-04 SK SK232-2000A patent/SK2322000A3/en unknown
- 1998-08-04 IL IL13438698A patent/IL134386A0/en unknown
- 1998-08-04 WO PCT/EP1998/004846 patent/WO1999009960A1/en not_active Ceased
- 1998-08-04 CA CA002299715A patent/CA2299715A1/en not_active Abandoned
- 1998-08-04 ID IDW20000282A patent/ID24885A/en unknown
- 1998-08-04 PL PL98338736A patent/PL338736A1/en unknown
- 1998-08-04 JP JP2000507351A patent/JP2001513547A/en active Pending
- 1998-08-21 ZA ZA987580A patent/ZA987580B/en unknown
-
2000
- 2000-02-18 NO NO20000814A patent/NO20000814L/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| HUP0004184A3 (en) | 2001-08-28 |
| EP1007016A1 (en) | 2000-06-14 |
| HUP0004184A2 (en) | 2001-04-28 |
| AU9338798A (en) | 1999-03-16 |
| DE19736520A1 (en) | 1999-02-25 |
| NO20000814D0 (en) | 2000-02-18 |
| ZA987580B (en) | 1999-02-23 |
| KR20010023176A (en) | 2001-03-26 |
| JP2001513547A (en) | 2001-09-04 |
| AU737379B2 (en) | 2001-08-16 |
| PL338736A1 (en) | 2000-11-20 |
| IL134386A0 (en) | 2001-04-30 |
| SK2322000A3 (en) | 2000-07-11 |
| ID24885A (en) | 2000-08-31 |
| CA2299715A1 (en) | 1999-03-04 |
| NO20000814L (en) | 2000-02-18 |
| TR200000408T2 (en) | 2000-09-21 |
| WO1999009960A1 (en) | 1999-03-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU737379B2 (en) | Identification for adhesive sheet-like dermal and trans- dermal therapeutic administration forms using an adhesive plaster as information carrier, and process for its production | |
| KR101354872B1 (en) | Drug storage and dispensing devices and systems comprising the same | |
| CN101730516A (en) | Storage and dispensing device for oral transmucosal dosage form administration | |
| BRPI0417757A (en) | frequency-assisted transdermal agent release method and system | |
| NZ277969A (en) | Transdermal drug delivery system containing a drug and a visible indicator | |
| CN110891647A (en) | Self-reminding patch | |
| CN115988997A (en) | Device for reducing bleeding and methods of making and using same | |
| CA2212885C (en) | Method and apparatus for indicating a dosage of medicine | |
| Wax et al. | Prehospital gastrointestinal decontamination of toxic ingestions: a missed opportunity | |
| JP3836308B2 (en) | Pharmaceutical packaging | |
| Jennings et al. | Medication safety: just a label away | |
| MXPA00001731A (en) | Flat systems for cutaneous and percutaneous administration involving a sticking-plaster as an information carrier, and method for producing such a plaster | |
| CN101268874A (en) | Disposable wristband with radio frequency identification tag | |
| CZ2000579A3 (en) | Marking for adhesive flat dermal and transdermal therapeutic administering methods by making use of plaster as information carrier, as ell as process for producing thereof | |
| Konarzewski et al. | Unrecognised fatal anaphylactic reaction to propofol or fentanyl. | |
| KR102866649B1 (en) | Transdermal Absorbable Patch that Visualizes the Elapsed Time of Use | |
| HK40016396A (en) | Self-reminding patch | |
| Nossiter et al. | A comparison of clinical efficacy of two delivery systems of salicylic acid in corn removal plasters | |
| Johnson | Medical identification card. | |
| JP3105885U (en) | Sticking label | |
| Cardew | The Mobile Unit in Action | |
| Jarman | Unification of Shelter Control | |
| Binks | Second Attack of Cerebrospinal Fever | |
| KRISHNA JAIN | Policies and Procedures | |
| US8690841B2 (en) | Wound care system |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed |